BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9848332)

  • 1. An audit of antiemetic use with CMF chemotherapy.
    Brown RS; Brown TK; Hoare D; Gaze MN
    Clin Oncol (R Coll Radiol); 1998; 10(5):313-7. PubMed ID: 9848332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Recent improvements in antiemetic therapy].
    Roila F; Palladino MA; Ciccarese G; Basurto C
    Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy.
    Massidda B; Ionta MT
    J Chemother; 1996 Jun; 8(3):237-42. PubMed ID: 8808724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective control of CMF-related emesis with high-dose dexamethasone: results of a double-blind crossover trial with metoclopramide and placebo.
    Pollera CF; Nardi M; Marolla P; Pinnaró P; Terzoli E; Giannarelli D
    Am J Clin Oncol; 1989 Dec; 12(6):524-9. PubMed ID: 2589233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.
    Levitt M; Warr D; Yelle L; Rayner HL; Lofters WS; Perrault DJ; Wilson KS; Latreille J; Potvin M; Warner E
    N Engl J Med; 1993 Apr; 328(15):1081-4. PubMed ID: 8455665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin.
    Mantovani G; Macciò A; Curreli L; Lampis B; Ghiani M; Bianchi A; Contu P
    Oncol Rep; 1998; 5(1):273-80. PubMed ID: 9458381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study.
    Chua DT; Sham JS; Kwong DL; Kwok CC; Yue A; Foo YC; Chan R
    Am J Clin Oncol; 2000 Apr; 23(2):185-91. PubMed ID: 10776982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose metoclopramide and dexamethasone as an antiemetic in chemotherapy of breast cancer.
    Gez E; Goodman S; Isacson R; Gerra C; Sulkes A
    Oncology; 1986; 43(3):173-5. PubMed ID: 3754627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy.
    Sigsgaard T; Herrstedt J; Andersen LJ; Havsteen H; Langer SW; Kjaerbøl AG; Lund H; Kjaer M; Dombernowsky P
    Br J Cancer; 1999 May; 80(3-4):412-8. PubMed ID: 10408847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis.
    Aapro MS; Thuerlimann B; Sessa C; De Pree C; Bernhard J; Maibach R;
    Ann Oncol; 2003 Feb; 14(2):291-7. PubMed ID: 12562658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal control of cyclophosphamide-induced emesis.
    Stewart A
    Oncology; 1996 Jun; 53 Suppl 1():32-8. PubMed ID: 8692548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose metoclopramide and dexamethasone as an antiemetic in outpatients receiving chemotherapy for breast cancer. Second study.
    Gez E; Warner-Efraty E; Ben-Yosef R; Ben-Baruch N; Yitzhaki N; Uziely B; Brufman G; Biran S
    Oncology; 1987; 44(4):237-9. PubMed ID: 3614813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed emesis induced by moderately emetogenic chemotherapy: do we need to treat all patients? The Italian Group for Antiemetic Research.
    Ann Oncol; 1997 Jun; 8(6):561-7. PubMed ID: 9261525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma.
    Numbenjapon T; Sriswasdi C; Mongkonsritragoon W; Leelasiri A; Prayoonwiwat W
    J Med Assoc Thai; 2002 Nov; 85(11):1156-63. PubMed ID: 12546311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis.
    Warr D; Willan A; Fine S; Wilson K; Davis A; Erlichman C; Rusthoven J; Lofters W; Osoba D; Laberge F
    J Natl Cancer Inst; 1991 Aug; 83(16):1169-73. PubMed ID: 1653363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer.
    Bosnjak SM; Nesković-Konstantinović ZB; Radulović SS; Susnjar S; Mitrovi LB
    J Chemother; 2000 Oct; 12(5):446-53. PubMed ID: 11128567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. An NCI Canada Clinical Trials Group Phase III Trial.
    Warr D; Wilan A; Venner P; Pater J; Kaizer L; Laberge F; Latreille J; Stewart D; O'Connell G; Osoba D
    Eur J Cancer; 1992; 29A(1):33-6. PubMed ID: 1332737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Use of dexamethasone as an antiemetic in patients with breast cancer treated with the CMF regimen].
    Domaradzka-Woźniak A; Wojtacki J; Dziewulska-Bokiniec A
    Przegl Lek; 1994; 51(5):203-5. PubMed ID: 7938648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of serotonin-receptor antagonist antiemetic therapy over successive courses of carboplatin-based chemotherapy.
    Markman MR; Peterson G; Kulp B; Markman M
    Gynecol Oncol; 2002 Jun; 85(3):435-7. PubMed ID: 12051870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.